rbm39 degrader rec-1245
Generic: RBM39 Degrader REC-1245
rbm39 degrader rec-1245: developed by 1 company · 1 clinical trial tracked.
rbm39 degrader rec-1245 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect rbm39 degrader rec-1245 to RXRX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could rbm39 degrader rec-1245 → RXRX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Unresectable
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) Unresectable | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Primary endpoint: Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)
InterventionalRandomizedopen170 targetStarted 2024-11Completion 2028-107 sites · Canada, United StatesRecursion Pharmaceuticals Inc.
Frequently asked questions
Who is developing rbm39 degrader rec-1245?
rbm39 degrader rec-1245 is being developed by RECURSION PHARMACEUTICALS, INC..
How many clinical trials involve rbm39 degrader rec-1245?
BioSniper tracks 1 clinical trial involving rbm39 degrader rec-1245.